Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes

被引:212
作者
Cheung, BMY [1 ]
Lauder, IJ
Lau, CP
Kumana, CR
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Stat & Actuarial Sci, Hong Kong, Hong Kong, Peoples R China
关键词
cardiovascular disease prevention; clinical trials; coronary heart disease; HMG-CoA reductase inhibitor; lipids; meta-analysis; statin;
D O I
10.1111/j.1365-2125.2003.02060.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Since 2002, there have been five major outcome trials of statins reporting findings from more than 47 000 subjects. As individual trial results differed, we performed a meta-analysis to ascertain the effectiveness and safety of statins overall and in subgroups. The aim of the study was to estimate the effect of statins on major coronary events and strokes, all-cause mortality and noncardiovascular mortality, and in different subgroups. Methods PubMed was searched for trials published in English. Randomized placebo-controlled statin trials with an average follow up of at least 3 years and at least 100 major coronary events were included. For each trial, the statin used, number and type of subjects, proportion of women, mean age and follow up, baseline and change in lipid profile, cardiovascular and non-cardiovascular outcomes were recorded. Results Ten trials involving 79 494 subjects were included in the meta-analysis. Due to heterogeneity, ALLHAT-LLT was excluded from some analyses. Stalin therapy reduced major coronary events by 27% (95% Cl 23, 30%), stroke by 18% (95%Cl 10, 25%) and all-cause mortality by 15% (95%Cl 8, 21%). There was a 4% (95%Cl -10, 3%) nonsignificant reduction in noncardiovascular mortality. The reduction in major coronary events is independent of gender and presence of hypertension or diabetes. The risk reduction was greater in smokers (P < 0.05). Coronary events were reduced by 23% (95%Cl 18, 29%) in pravastatin trials and 29% (95%Cl 25, 33%) in five trials using other statins. Pravastatin reduced strokes by 12% (95%Cl 1, 21%) whilst other statins reduced strokes by 24% (95%Cl 16, 32%) (P = 0.04). Conclusions Statins reduce coronary events, strokes and all-cause mortality without increasing noncoronary mortality. The benefits accrue in men and women, hypertensives and normotensives, diabetics and nondiabetics, and particularly in smokers. Pravastatin appears to have less impact on strokes.
引用
收藏
页码:640 / 651
页数:12
相关论文
共 36 条
[1]   CARDIOVASCULAR-DISEASE RISK PROFILES [J].
ANDERSON, KM ;
ODELL, PM ;
WILSON, PWF ;
KANNEL, WB .
AMERICAN HEART JOURNAL, 1991, 121 (01) :293-298
[2]  
[Anonymous], 2002, JAMA
[3]   Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men [J].
Assmann, G ;
Schulte, H ;
vonEckardstein, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (14) :1179-1184
[4]   Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].
Athyros, VG ;
Papageorgiou, AA ;
Mercouris, BR ;
Athyrou, VV ;
Symeonidis, AN ;
Basayannis, EO ;
Demitriadis, DS ;
Kontopoulos, AG .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228
[5]   PREVALENCE OF HYPERTENSION IN THE US ADULT-POPULATION - RESULTS FROM THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-1991 [J].
BURT, VL ;
WHELTON, P ;
ROCCELLA, EJ ;
BROWN, C ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D .
HYPERTENSION, 1995, 25 (03) :305-313
[6]  
Campeau L, 1997, NEW ENGL J MED, V336, P153
[7]   Effectiveness of lipid lowering drugs in general practice - Study had two major flaws [J].
Cheung, BMY ;
Kumana, CR .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7405) :51-51
[8]  
Cheung BMY, 2001, NEW ZEAL MED J, V114, P214
[9]  
Cheung BMY, 2001, LANCET, V357, P880
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497